The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...
An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback